Cytokinetics Inc (CYTK) · Nov 4, 2026 · Earnings
Beat — Revenue $47.6M vs ~$41.9M consensus; EPS $(1.37) vs $(1.44) consensus
Cytokinetics earnings show MYQORZO sales accelerating ahead of consensus, with the nHCM filing plan intact and heavy launch spending continuing.
Cytokinetics is moving from a development-stage biotech into the early commercial launch of MYQORZO, while using aficamten’s positive ACACIA-HCM data to pursue a broader non-obstructive HCM label. The prior quarter had already established launch momentum and a planned Q4 2026 nHCM filing, so the main new information here is the pace of revenue conversion rather than a change in strategic direction.
The launch is running ahead of the near-term bar. Third-quarter revenue of $47.6 million beat the published consensus of roughly $41.9 million, while adjusted expectations were for a $(1.44) per-share loss versus the reported $(1.37). MYQORZO generated $44.5 million, including $43.1 million in the U.S. and $1.4 million in Europe, a meaningful step up from the $25.3 million reported in the second quarter.
| Q3 2026 | Q3 2025 | Consensus / comparison | |
|---|---|---|---|
| Total revenue (Financial Results) | $47.6M (+2,357%) | $1.9M | ~$41.9M |
| MYQORZO revenue (Financial Results) | $44.5M | $0 | |
| EPS, basic and diluted (Income Statement) | $(1.37) | $(2.55) | ~$(1.44) |
| Net loss (Income Statement) | $190.1M | $306.2M | |
| Cash, equivalents and investments (Cash section) | $1.6B | $1.7B at Jun. 30, 2026 | |
| FY2026 combined R&D + SG&A guidance (Guidance) | $860M–$890M | Reaffirmed |
The revenue beat is more important than the smaller accounting loss. The year-over-year loss improvement was helped by the absence of the $121.2 million debt-conversion expense recorded in the prior-year quarter, so it does not represent an equivalent improvement in underlying profitability. Meanwhile, R&D was broadly stable at $99.3 million, but SG&A rose to $113.1 million from $69.5 million as Cytokinetics funded the MYQORZO commercial rollout.
The pipeline and regulatory path are advancing, but mostly as expected. Cytokinetics reiterated its plan to submit the supplemental U.S. application for nHCM in Q4 2026 and the European variation in early 2027. The U.K. authorization, NICE recommendation, and positive ACACIA-HCM readout strengthen the commercial setup, but those developments were already substantially known before this filing. 〔0〕
Cash remains ample, but the company is still spending heavily ahead of scale. Cash, equivalents and investments declined from approximately $1.7 billion at June 30 to $1.6 billion at September 30, while full-year operating-expense guidance was reaffirmed. That gives the launch and regulatory programs financial room, but the quarter does not yet show the commercial business approaching profitability.
Bottom line: This is a genuine earnings beat driven by faster-than-expected MYQORZO uptake, while the broader aficamten expansion story remains on schedule. It improves the early commercial-launch narrative, but does not yet rewrite the company’s spending or profitability profile.
Supplemental NDA filing for nHCM, Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!